The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest

Manuel D. Haschka, Claudia Soratroi, Susanne Kirschnek, Georg Häcker, Richard Hilbe, Stephan Geley, Andreas Villunger () and Luca L. Fava ()
Additional contact information
Manuel D. Haschka: Biocenter, Medical University Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria
Claudia Soratroi: Biocenter, Medical University Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria
Susanne Kirschnek: Institute for Medical Microbiology and Hygiene, University Medical Center Freiburg
Georg Häcker: Institute for Medical Microbiology and Hygiene, University Medical Center Freiburg
Richard Hilbe: Biocenter, Medical University Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria
Stephan Geley: Biocenter, Medical University Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria
Andreas Villunger: Biocenter, Medical University Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria
Luca L. Fava: Biocenter, Medical University Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria

Nature Communications, 2015, vol. 6, issue 1, 1-13

Abstract: Abstract Cell death on extended mitotic arrest is considered arguably most critical for the efficacy of microtubule-targeting agents (MTAs) in anticancer therapy. While the molecular machinery controlling mitotic arrest on MTA treatment, the spindle assembly checkpoint (SAC), appears well defined, the molecular components executing cell death, as well as factors connecting both networks remain poorly understood. Here we conduct a mini screen exploring systematically the contribution of individual BCL2 family proteins at single cell resolution to death on extended mitotic arrest, and demonstrate that the mitotic phosphorylation of BCL2 and BCLX represent a priming event for apoptosis that is ultimately triggered by NOXA-dependent MCL1 degradation, enabling BIM-dependent cell death. Our findings provide a comprehensive model for the initiation of apoptosis in cells stalled in mitosis and provide a molecular basis for the increased efficacy of combinatorial treatment of cancer cells using MTAs and BH3 mimetics.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms7891 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7891

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms7891

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().